Abstract：
Tuberculosis (TB) is a significant global health threat, and cases of infection with non-tuberculous mycobacteria (NTM) causing lung disease (NTM-LD) are rising. Bacteriophages and their gene products have garnered interest as potential therapeutic options for bacterial infections. Here, we have compiled information on bacteriophages and their products that can kill Mycobacterium tuberculosis or NTM. We summarize the mechanisms whereby viable phages can access macrophage-resident bacteria and not elicit immune responses, review methodologies of pharmaceutical product development containing mycobacteriophages and their gene products, mainly lysins, in the context of drug regulatory requirements and we discuss industrially relevant methods for producing pharmaceutical products comprising mycobacteriophages, emphasizing delivery of mycobacteriophages to the lungs. We conclude with an outline of some recent case studies on mycobacteriophage therapy.
摘要：
结核病（TB）是一个重大的全球健康威胁，非结核分枝杆菌（NTM）感染导致肺部疾病（NTM-LD）的病例正在上升。噬菌体及其基因产物作为细菌感染的潜在治疗选择已经引起了人们的兴趣。这里,我们已经收集了可以杀死结核分枝杆菌或NTM的噬菌体及其产品的信息。我们总结了活的噬菌体可以进入巨噬细胞驻留细菌而不引起免疫反应的机制，审查包含分枝杆菌噬菌体及其基因产物的药物产品开发方法，主要是溶素，在药物监管要求的背景下，我们讨论了生产包含分枝杆菌噬菌体的药物产品的工业相关方法，强调将分枝杆菌噬菌体输送到肺部。最后，我们概述了一些有关分枝杆菌噬菌体治疗的最新案例研究。
